Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Clinical Data on Cryoablation For The Treatment Of Early Stage Breast Cancer To Be Presented At Susan G. Komen San Diego
  • USA - English


News provided by

90210 Surgery Medical Center

Mar 01, 2017, 05:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Dennis Holmes
Dr. Dennis Holmes

BEVERLY HILLS, CA (PRWEB) March 01, 2017 -- Breast Surgeon, Dr. Dennis Holmes of 90210 Surgery Medical Center will review minimally invasive cryoablation for the treatment of early stage breast cancer and where it fits in the treatment paradigm at Susan G. Komen San Diego’s Annual Dinner Symposium, “Screens, Genes & The Choices We Make.” The event brings together leading cancer and wellness experts to share the latest innovations in breast cancer research, treatment and holistic well-being. The symposium will take place on Thursday, March 16, 2017 at the San Diego Del Mar Marriott.

I am thrilled to partner with Komen San Diego, as we share similar goals - to save lives and pursue the best breast cancer treatments.

Post this

Dr. Holmes is an internationally renowned breast surgeon and cancer researcher currently serving as Interim Director of the Margie Petersen Breast Center at Providence St. John’s Health Center and Interim Director, John Wayne Cancer Institute Breast Surgery Fellowship Program. Formerly, Dr. Holmes held the positions of Chief Breast Surgeon and Medical Director of the Los Angeles Center for Women’s Health, and Chief Breast Cancer Surgeon, and Breast Cancer Research Committee Co-Chair at the University of Southern California Kenneth Norris Comprehensive Cancer Center. Dr. Holmes has been a pioneer in the field of minimally invasive breast surgery, including intraoperative radiotherapy, lymph node-sparing surgery and cryoablation

“I am thrilled to partner with Komen San Diego, as we share similar goals - to save lives and pursue the best breast cancer treatments,” said Dr. Holmes.

Currently, the standard of care for early stage breast cancer is surgery (e.g. lumpectomy, mastectomy) and sentinel node biopsy followed by breast radiotherapy and adjuvant endocrine and/or chemotherapy. Although surgery offers tumor removal and margin verification, a major drawback of surgery is the cosmetic and functional impairment of the breast resulting from volume changes, scar formation, nipple displacement, sensation changes, skin/scar retraction, and re-excision rate.

Dr. Holmes was an investigator in the National Cancer Institute Z1072 Clinical Trial sponsored by the Alliance for Clinical Trials in Oncology. The trial examined cryoablation for the treatment of early stage breast cancer. In a 5-year multicenter study, cryoablation was shown to be 92% effective for complete ablation of invasive breast tumors ≤2 cm and 100% effective for complete ablation of invasive ductal breast cancer tumors <1.0 cm. Results from this breast cancer study (ACOSOG Z1072), which included a 5-year follow-up, were published in the Annals of Surgical Oncology. The Visica® 2 Treatment System developed by Sanarus Technologies, was the exclusive device used in the Z1072 study.

“Cryoablation is a very promising alternative to traditional surgery for early stage breast cancer. Cryoablation minimizes changes in breast volume and nipple position, and avoids prominent scars,” explained Dr. Holmes. “The outstanding results of Z0172 inspired me to start the FROST Clinical Study, for which I now serve as Principal Investigator.”

The FROST Clinical Study is the evolution of data from Z1072, which examines the rate of successful tumor ablation in patients treated with cryoablation of the primary tumor instead of surgical removal of early stage breast cancer. The FROST Clinical Study is currently enrolling women age 50 and older with core needle biopsy proven clinical stage I, T1, (≤1.5 cm) clinically node negative (N0), unifocal, hormone receptor positive and HER2/neu-negative invasive ductal carcinoma.

Cryoablation with the Visica 2 Treatment System is a nonsurgical option for patients that have been diagnosed with early stage breast cancer, is visible on sonogram, and has been confirmed with a biopsy. This procedure has many benefits including: under 30-minutes, local anesthesia, in-office, excellent cosmesis, cost efficient, and quick patient recovery. Cryoablation is a viable option to surgery that results in complete early stage tumor ablation.

About Dr. Holmes
Dr. Holmes serves in the leadership of several national surgical societies and is a frequent lecturer at national conferences. He is a member of the education committee of the American Society of Breast Surgeons. Dr. Holmes is a Fellow of the American College of Surgeons and was also recently selected as Board Chair and President of the TARGIT Collaborative Group, a national research and education organization. Widely respected by colleagues for his innovative approach to breast cancer care, Dr. Holmes has gained worldwide acclaim for his pioneering research in targeted intraoperative radiotherapy. Dr. Holmes believes wholeheartedly that, with proper treatment, most women diagnosed with breast cancer will live a long, fulfilling life—a life both richer and more meaningful than they could have ever imagined. Find out more at http://www.drholmesmd.com

About Sanarus Technologies
In 2001, the Visica® 2 Treatment System was the first device available for cryoablation of fibroadenomas. Since then, our system has been used to successfully treat thousands of patients. The Visica 2 Treatment System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. At Sanarus, we develop innovative solutions for the nonsurgical treatment of breast tumors. We are headquartered in Pleasanton, CA, and all our products are manufactured in the USA. Find out more at http://www.sanarus.com

ABOUT SUSAN G. KOMEN SAN DIEGO®:
Since its inception in 1995, Komen San Diego has granted more than $18 million to research and local non-profits who provide everything from free diagnostic mammograms, meal delivery, temporary financial aid, transportation and more. Seventy-five percent of every dollar raised in San Diego stays in San Diego County to fund breast health services for uninsured and underinsured women and their families. The remaining 25 percent funds international breast cancer research. In fact, next to the U.S. government, Susan G. Komen® is the largest funder of breast cancer research in the world. For more information, please visit http://www.komensandiego.org. Connect with us on Facebook and Twitter and Instagram.

Gerald Coronado, 90210 Surgery Medical Center, http://www.drholmesmd.com, +1 (818) 539-1985, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.